TY - JOUR AU - Chapman, P. B. AU - Einhorn, L. H. AU - Meyers, M. L. PY - 1999 DA - 1999// TI - Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma JO - J Clin Oncol VL - 17 UR - https://doi.org/10.1200/JCO.1999.17.9.2745 DO - 10.1200/JCO.1999.17.9.2745 ID - Chapman1999 ER - TY - JOUR AU - Long, G. V. AU - Weber, J. S. AU - Infante, J. R. PY - 2016 DA - 2016// TI - Overall survival and durable responses in patients with BRAF V600–mutant metastatic melanoma receiving Dabrafenib combined with Trametinib JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.62.9345 DO - 10.1200/JCO.2015.62.9345 ID - Long2016 ER - TY - JOUR AU - Dummer, R. AU - Ascierto, P. A. AU - Gogas, H. J. PY - 2018 DA - 2018// TI - Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30497-2 DO - 10.1016/S1470-2045(18)30497-2 ID - Dummer2018 ER - TY - STD TI - Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018. ID - ref4 ER - TY - JOUR AU - Schachter, J. AU - Ribas, A. AU - Long, G. V. PY - 2017 DA - 2017// TI - Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) JO - Lancet VL - 390 UR - https://doi.org/10.1016/S0140-6736(17)31601-X DO - 10.1016/S0140-6736(17)31601-X ID - Schachter2017 ER - TY - STD TI - Long GV, Schachter J, Ribas A, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. Journal of Clinical Ocology. 2018;36. ID - ref6 ER - TY - JOUR AU - Hodi, F. S. AU - O'Day, S. J. AU - McDermott, D. F. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Schadendorf, D. AU - Hodi, F. S. AU - Robert, C. PY - 2015 DA - 2015// TI - Pooled analysis of Long-term survival data from phase II and phase III trials of Ipilimumab in Unresectable or metastatic melanoma JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.56.2736 DO - 10.1200/JCO.2014.56.2736 ID - Schadendorf2015 ER - TY - JOUR AU - Robert, C. AU - Long, G. V. AU - Brady, B. PY - 2015 DA - 2015// TI - Nivolumab in previously untreated melanoma without BRAF mutation JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412082 DO - 10.1056/NEJMoa1412082 ID - Robert2015 ER - TY - JOUR AU - Robert, C. AU - Schachter, J. AU - Long, G. V. PY - 2015 DA - 2015// TI - Pembrolizumab versus Ipilimumab in advanced melanoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1503093 DO - 10.1056/NEJMoa1503093 ID - Robert2015 ER - TY - STD TI - Dummer R, Ascierto PA, Gogas H, et al. Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. In: 2018 ASCO Annual Meeting. Chicago, IL: J Clin Oncol; 2018:abst 9504. ID - ref11 ER - TY - JOUR AU - Ascierto, P. A. AU - Ferrucci, P. F. AU - Stephens, R. PY - 2018 DA - 2018// TI - KEYNOTE-022 part 3: phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdx779 DO - 10.1093/annonc/mdx779 ID - Ascierto2018 ER - TY - JOUR AU - Minor, D. R. AU - Puzanov, I. AU - Callahan, M. K. AU - Hug, B. A. AU - Hoos, A. PY - 2015 DA - 2015// TI - Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab JO - Pigment cell & melanoma research VL - 28 UR - https://doi.org/10.1111/pcmr.12383 DO - 10.1111/pcmr.12383 ID - Minor2015 ER - TY - JOUR AU - Hugo, W. AU - Zaretsky, J. M. AU - Sun, L. PY - 2016 DA - 2016// TI - Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma JO - Cell VL - 165 UR - https://doi.org/10.1016/j.cell.2016.02.065 DO - 10.1016/j.cell.2016.02.065 ID - Hugo2016 ER - TY - JOUR AU - Hu-Lieskovan, S. AU - Robert, L. AU - Homet Moreno, B. AU - Ribas, A. PY - 2014 DA - 2014// TI - Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.52.1377 DO - 10.1200/JCO.2013.52.1377 ID - Hu-Lieskovan2014 ER - TY - JOUR AU - Weber, J. S. AU - Kudchadkar, R. R. AU - Yu, B. PY - 2013 DA - 2013// TI - Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2013.51.4802 DO - 10.1200/JCO.2013.51.4802 ID - Weber2013 ER - TY - JOUR AU - Weber, J. AU - Martinez, A. AU - Roder, H. PY - 2015 DA - 2015// TI - Pre-treatment patient selection for nivolumab benefit based on serum mass spectra JO - Journal for immunotherapy of cancer VL - 3 UR - https://doi.org/10.1186/2051-1426-3-S2-P103 DO - 10.1186/2051-1426-3-S2-P103 ID - Weber2015 ER - TY - JOUR AU - Grossi, F. AU - Rijavec, E. AU - Biello, F. PY - 2017 DA - 2017// TI - Evaluation of a pretreatment serum tests for nivolumab benefit in patients with non-small cell lung cancer JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2016.11.1870 DO - 10.1016/j.jtho.2016.11.1870 ID - Grossi2017 ER - TY - JOUR AU - Zahorec, R. PY - 2001 DA - 2001// TI - Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill JO - Bratisl Lek Listy VL - 102 ID - Zahorec2001 ER - TY - JOUR AU - Capone, M. AU - Giannarelli, D. AU - Mallardo, D. PY - 2018 DA - 2018// TI - Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab JO - J Immunother Cancer VL - 6 UR - https://doi.org/10.1186/s40425-018-0383-1 DO - 10.1186/s40425-018-0383-1 ID - Capone2018 ER - TY - JOUR AU - Ferrucci, P. F. AU - Ascierto, P. A. AU - Pigozzo, J. PY - 2018 DA - 2018// TI - Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdx059 DO - 10.1093/annonc/mdx059 ID - Ferrucci2018 ER - TY - JOUR AU - Subramanian, A. AU - Tamayo, P. AU - Mootha, V. K. PY - 2005 DA - 2005// TI - Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles JO - Proc Natl Acad Sci U S A VL - 102 UR - https://doi.org/10.1073/pnas.0506580102 DO - 10.1073/pnas.0506580102 ID - Subramanian2005 ER - TY - JOUR AU - Markiewski, M. M. AU - DeAngelis, R. A. AU - Benencia, F. PY - 2008 DA - 2008// TI - Modulation of the antitumor immune response by complement JO - Nat Immunol VL - 9 UR - https://doi.org/10.1038/ni.1655 DO - 10.1038/ni.1655 ID - Markiewski2008 ER - TY - JOUR AU - Crusz, S. M. AU - Balkwill, F. R. PY - 2015 DA - 2015// TI - Inflammation and cancer: advances and new agents JO - Nat Rev Clin Oncol VL - 12 UR - https://doi.org/10.1038/nrclinonc.2015.105 DO - 10.1038/nrclinonc.2015.105 ID - Crusz2015 ER -